DIANE GONZALES: Open Payments
NPI 1992848774 · OPELOUSAS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,158 in 70 payments from 10 companies in 2025. Trend: 2023 $730 · 2024 $733 · 2025 $1,158
Food & beverage: $1,158
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 18 | $332 |
| Alkermes, Inc. | 11 | $175 |
| Teva Pharmaceuticals USA, Inc. | 13 | $156 |
| Axsome Therapeutics, Inc. | 7 | $118 |
| E.R. Squibb & Sons, L.L.C. | 5 | $99 |
| ABBVIE INC. | 5 | $90 |
| Otsuka America Pharmaceutical, Inc. | 3 | $54 |
| Janssen Pharmaceuticals, Inc | 3 | $53 |
| Vanda Pharmaceuticals Inc. | 3 | $49 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $33 |
Products named: INGREZZA, ARISTADA, UZEDY, Auvelity, COBENFY, VRAYLAR, ABILIFY ASIMTUFII, INVEGA SUSTENNA.
Industry payments across LA — which companies pay providers there.
